{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:24Z","timestamp":1740144024060,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T00:00:00Z","timestamp":1464998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40256-016-0174-3","type":"journal-article","created":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T11:28:44Z","timestamp":1465039724000},"page":"285-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction"],"prefix":"10.1007","volume":"16","author":[{"given":"John D.","family":"Whalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori D.","family":"Bash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipek","family":"Ozer-Stillman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,4]]},"reference":[{"key":"174_CR1","unstructured":"World Health Organization (WHO). Global status report on noncommunicable diseases, 2014: attaining the nine global noncommunicable diseases targets; a shared responsibility. Geneva: World Health Organization; 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/148114\/1\/9789241564854_eng.pdf . Accessed 28 Jan 2015."},{"key":"174_CR2","unstructured":"British Heart Foundation (BHF). BHF Cardiovascular disease statistics, UK factsheet. London: British Heart Foundation; 2015. https:\/\/www.bhf.org.uk\/research\/heart-statistics . Accessed 28 Jan 2015."},{"issue":"1","key":"174_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/CIR.0b013e318282ab8f","volume":"127","author":"AS Go","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics\u20132013 update: a report from the American Heart Association. Circulation. 2013;127(1):143\u201352. doi: 10.1161\/CIR.0b013e318282ab8f .","journal-title":"Circulation."},{"issue":"24","key":"174_CR4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228. doi: 10.1016\/j.jacc.2014.09.017 .","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"174_CR5","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999\u20133054. doi: 10.1093\/eurheartj\/ehr236 .","journal-title":"Eur Heart J."},{"issue":"38","key":"174_CR6","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003. doi: 10.1093\/eurheartj\/eht296 .","journal-title":"Eur Heart J."},{"issue":"19","key":"174_CR7","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry (REACH). Eur Heart J. 2009;30(19):2318\u201326. doi: 10.1093\/eurheartj\/ehp355 .","journal-title":"Eur Heart J."},{"issue":"18","key":"174_CR8","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1021\/jm0603670","volume":"49","author":"S Chackalamannil","year":"2006","unstructured":"Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem. 2006;49(18):5389\u2013403. doi: 10.1021\/jm0603670 .","journal-title":"J Med Chem."},{"issue":"19","key":"174_CR9","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1021\/jm0502236","volume":"48","author":"S Chackalamannil","year":"2005","unstructured":"Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem. 2005;48(19):5884\u20137. doi: 10.1021\/jm0502236 .","journal-title":"J Med Chem."},{"issue":"9850","key":"174_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/s0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380(9850):1317\u201324. doi: 10.1016\/s0140-6736(12)61269-0 .","journal-title":"Lancet."},{"key":"174_CR11","unstructured":"United States Food and Drug Adminstration (FDA). Drug Trials Snapshot: Zontivity (vorapaxar). Silver Spring: US FDA; 2015. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm423935.htm . Accessed 29 Feb 2016."},{"key":"174_CR12","unstructured":"European Medicines Agency (EMA). Zontivity (vorapaxar): the European public assessment report (EPAR) for the approval of Zontivity for use in the European Union. London: EMA; 2015 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/002814\/human_med_001839.jsp . Accessed 29 Feb 2016."},{"key":"174_CR13","unstructured":"Gavalova L, Weston C, for MINAP (Myocardial Ischaemia National Audit Project). How the NHS cares for patients with heart attack. Annual Public Report, April 2011\u2013March 2012. London: Healthcare Quality Improvement Partnership; 2012. http:\/\/www.ucl.ac.uk\/nicor\/audits\/minap\/documents\/annual_reports\/minap2012publicreport . Accessed 26 Feb 2013."},{"key":"174_CR14","unstructured":"HESonline\u2122. Hospital Episode Statistics, Admitted Patient Care\u2014England, 2011\u20132012. Main operations, 3 characters table. Spreadsheet name: main procedures and interventions: 3 character. Leeds: Health and Social Care Informations Centre; 2012. http:\/\/www.hscic.gov.uk\/searchcatalogue?productid=9161&q=title%3a%22Hospital+Episode+Statistics%2c+Admitted+patient+care+-+England%22&sort=Relevance&size=10&page=1#top . Accessed 26 Feb 2013."},{"key":"174_CR15","doi-asserted-by":"publisher","unstructured":"Greenhalgh J, Bagust A, Boland B, Saborido CM, Fleeman N, McLeod C, et al. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: a single technology appraisal. Health Technol Assess. 2009;14 Suppl 1(Article 5):31\u20138. doi: 10.3310\/hta14Suppl1\/05 .","DOI":"10.3310\/hta14Suppl1\/05"},{"key":"174_CR16","unstructured":"Greenhalgh J, Bagust A, Boland A, Blundell M, Lai M, Dundar Y et al. Ticagrelor for the treatment of acute coronary syndromes: a single technology appraisal. This report was commissioned by the NIHR HTA Programme as Project Number 08\/240. Liverpool: Liverpool Reviews and Implementation Group (LRiG), The University of Liverpool; 2011. http:\/\/www.nice.org.uk\/guidance\/ta236\/documents\/acute-coronary-syndromes-ticagrelor-evidence-review-group-report2 . Accessed 28 Jan 2015."},{"issue":"11","key":"174_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. doi: 10.1056\/NEJMoa0904327 .","journal-title":"N Engl J Med."},{"issue":"6","key":"174_CR18","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1161\/CIRCULATIONAHA.105.171600","volume":"113","author":"T Thom","year":"2006","unstructured":"Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics\u20142006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85\u2013151. doi: 10.1161\/CIRCULATIONAHA.105.171600 .","journal-title":"Circulation."},{"issue":"15","key":"174_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404\u201313. doi: 10.1056\/NEJMoa1200933 .","journal-title":"N Engl J Med."},{"issue":"3","key":"174_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.rec.2012.10.006","volume":"66","author":"JI Cuende","year":"2013","unstructured":"Cuende JI. Vascular age derived from SCORE and the European guidelines on cardiovascular disease prevention in clinical practice (Version 2012). Rev Esp Cardiol (Engl Ed). 2013;66(3):241. doi: 10.1016\/j.rec.2012.10.006 .","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"42","key":"174_CR21","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","volume":"35","author":"M Nichols","year":"2014","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950\u20139. doi: 10.1093\/eurheartj\/ehu299 .","journal-title":"Eur Heart J."},{"issue":"19","key":"174_CR22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"DL Bhatt","year":"2007","unstructured":"Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982\u20138. doi: 10.1016\/j.jacc.2007.03.025 .","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"174_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502. doi: 10.1056\/NEJMoa010746 .","journal-title":"N Engl J Med."},{"issue":"7329","key":"174_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","unstructured":"Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ."},{"issue":"9038","key":"174_CR25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329\u201339.","journal-title":"Lancet."},{"key":"174_CR26","unstructured":"Office for National Statistics. Historic and projected mortality data from the period and cohort life tables, 2012-based, United Kingdom, 1981\u20132062. Statistical Bulletin. London: ONS; 2013. http:\/\/www.ons.gov.uk\/ons\/rel\/lifetables\/historic-and-projected-data-from-the-period-and-cohort-life-tables\/2012-based\/stb-2012-based.html . Accessed 29 May 2014."},{"key":"174_CR27","unstructured":"Office for National Statistics. Death registrations summary tables, England and Wales, 2012. Statistical Bulletin. London: ONS; 2013. http:\/\/www.ons.gov.uk\/ons\/dcp171778_317087.pdf . Accessed 29 May 2014."},{"issue":"9","key":"174_CR28","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/hs0901.094253","volume":"32","author":"H Bronnum-Hansen","year":"2001","unstructured":"Bronnum-Hansen H, Davidsen M, Thorvaldsen P, Danish MSG. Long-term survival and causes of death after stroke. Stroke. 2001;32(9):2131\u20136.","journal-title":"Stroke."},{"issue":"6","key":"174_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989x11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800\u20134. doi: 10.1177\/0272989x11401031 .","journal-title":"Med Decis Making."},{"issue":"6","key":"174_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jval.2012.05.003","volume":"15","author":"R Ara","year":"2012","unstructured":"Ara R, Wailoo A. Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health. 2012;15(6):971\u20134. doi: 10.1016\/j.jval.2012.05.003 .","journal-title":"Value Health."},{"issue":"2","key":"174_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jacc.2004.10.034","volume":"45","author":"J Kim","year":"2005","unstructured":"Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KA, et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol. 2005;45(2):221\u20138. doi: 10.1016\/j.jacc.2004.10.034 .","journal-title":"J Am Coll Cardiol."},{"key":"174_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","volume":"15","author":"LS Matza","year":"2015","unstructured":"Matza LS, Stewart KD, Gandra SR, Delio PR, Fenster BE, Davies EW, et al. Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Serv Res. 2015;15:173. doi: 10.1186\/s12913-015-0772-9 .","journal-title":"BMC Health Serv Res."},{"issue":"9335","key":"174_CR33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(02)09894-X","volume":"360","author":"KA Fox","year":"2002","unstructured":"Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360(9335):743\u201351.","journal-title":"Lancet."},{"issue":"3","key":"174_CR34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","volume":"21","author":"TO Tengs","year":"2003","unstructured":"Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191\u2013200.","journal-title":"Pharmacoeconomics."},{"issue":"Suppl 1","key":"174_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00019053-200321001-00005","volume":"21","author":"P Youman","year":"2003","unstructured":"Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21(Suppl 1):43\u201350.","journal-title":"Pharmacoeconomics."},{"issue":"31","key":"174_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15310","volume":"15","author":"J Greenhalgh","year":"2011","unstructured":"Greenhalgh J, Bagust A, Boland A, Saborido CM, Oyee J, Blundell M, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess. 2011;15(31):1\u2013178. doi: 10.3310\/hta15310 .","journal-title":"Health Technol Assess."},{"issue":"6","key":"174_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20136. Value Health. 2012;15(6):835\u201342. doi: 10.1016\/j.jval.2012.04.014 .","journal-title":"Value Health."},{"key":"174_CR38","volume-title":"Discrete event simulation for health technology assessment, version date: 20150914","author":"JJ Caro","year":"2016","unstructured":"Caro JJ, M\u00f6ller J, Karnon J, Stahl J, Ishak J. Discrete event simulation for health technology assessment, version date: 20150914. Boca Raton: CRC Press, Taylor & Francis Group; 2016."},{"issue":"2 Pt 1","key":"174_CR39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","volume":"139","author":"RB D\u2019Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272\u201381.","journal-title":"Am Heart J."},{"issue":"1 Pt 2","key":"174_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293\u20138.","journal-title":"Am Heart J."},{"issue":"6","key":"174_CR41","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1524-4733.2009.00529.x","volume":"12","author":"J Chen","year":"2009","unstructured":"Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, et al. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. Value Health. 2009;12(6):872\u20139. doi: 10.1111\/j.1524-4733.2009.00529.x .","journal-title":"Value Health."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0174-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0174-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:44:37Z","timestamp":1498304677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0174-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2016,6,4]]}}}